This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

Engagements

CRA represents pharmaceutical manufacturers in pricing MDL

CRA provided expert testimony in litigation involving allegations that fraudulent reporting of list prices by pharmaceutical manufacturers affected reimbursement by insurers. CRA’s analyses addressed important features underlying pricing and reimbursement in the pharmaceutical industry, including the role of list prices and price reporting publications, the evolution of pricing mechanisms as a basis for reimbursement, and information held by various parties concerning pharmaceutical acquisition costs.

Key contacts

Related insights

Explore our thinking

Upcoming events

See all events